Jazz Pharmaceuticals JAZZ Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's other income (expense)?
- Jazz Pharmaceuticals (JAZZ) reported other income (expense) of -$3.9M in Q1 2026.
- How has Jazz Pharmaceuticals's other income (expense) changed year-over-year?
- Jazz Pharmaceuticals's other income (expense) decreased by 160.0% year-over-year, from $6.5M to -$3.9M.
- What is the long-term trend for Jazz Pharmaceuticals's other income (expense)?
- Over 2 years (2021 to 2024), Jazz Pharmaceuticals's other income (expense) has grown at a 33.9% compound annual growth rate (CAGR), from -$10.03M to -$17.98M.
- What does other income (expense) mean?
- The net result of financial activities not related to the company's core business operations.
- How do you interpret other income (expense)?
- Fluctuations often reflect changes in interest rate environments, currency volatility, or one-time non-operating events.
- How does other income (expense) compare across companies?
- Varies significantly based on capital structure and global exposure; peers with high debt or international operations typically show higher volatility.